Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

NCT01752920 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Derazantinib low dose range
DRUG: Derazantinib middle dose range
DRUG: Derazantinib high dose range
DRUG: Derazantinib at recommended phase 2 dose (RP2D)

Sponsor

Basilea Pharmaceutica

Collaborators

[object Object]